Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01567930
Title Temsirolimus as Second-line Therapy in HCC
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Tennessee Cancer Institute
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Boston Baskin Cancer Foundation RECRUITING Memphis Tennessee 38120 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field